Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.80 |
| ▸ | P2RY1 | P47900 | 6/20 | 0.73 |
| ▸ | ENPP1 | P22413 | 3/20 | 0.73 |
| ▸ | P2RX1 | P51575 | 3/20 | 0.70 |
| ▸ | P2RX3 | P56373 | 3/20 | 0.70 |
| ▸ | P2RX2 | Q9UBL9 | 2/20 | 0.70 |
| ▸ | P2RY2 | P41231 | 2/20 | 0.67 |
| ▸ | P2RX4 | Q99571 | 2/20 | 0.67 |
| ▸ | SRC | P12931 | 1/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.67 |
| ▸ | DTYMK | P23919 | 2/20 | 0.66 |
| ▸ | RNASEL | Q05823 | 1/20 | 0.65 |
| ▸ | MACROD2 | A1Z1Q3 | 1/20 | 0.63 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.63 |
| ▸ | MACROD1 | Q9BQ69 | 1/20 | 0.63 |
| ▸ | TRPM2 | O94759 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5044161 | 1.00 | POLB (0.80) | POLBP2RY1ENPP1P2RX1P2RX3 | |
| SCHEMBL29350133 | 1.00 | POLB (0.80) | POLBP2RY1ENPP1P2RX1P2RX3 | |
| SCHEMBL29702495 | 1.00 | POLB (0.80) | POLBP2RY1ENPP1P2RX1P2RX3 | |
| SCHEMBL14471000 | 1.00 | POLB (0.80) | POLBP2RY1ENPP1P2RX1P2RX3 | |
| SCHEMBL18785117 | 1.00 | POLB (0.80) | POLBP2RY1ENPP1P2RX1P2RX3 | |
| SCHEMBL78250 | 1.00 | POLB (0.80) | POLBP2RY1ENPP1P2RX1P2RX3 | |
| SCHEMBL889289 | 1.00 | POLB (0.80) | POLBP2RY1ENPP1P2RX1P2RX3 | |
| SCHEMBL703733 | 1.00 | POLB (0.80) | POLBP2RY1ENPP1P2RX1P2RX3 | |
| SCHEMBL31211719 | 0.99 | POLB (0.81) | POLBP2RY1ENPP1P2RX1P2RX3 | |
| SCHEMBL2508784 | 0.99 | POLB (0.81) | POLBP2RY1ENPP1P2RX1P2RX3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250369027-A1 | SUBSTRATE CLEAVAGE FOR NUCLEIC ACID SYNTHESIS | TWIST BIOSCIENCE CORP (US) | 2025-12-04 | — | — | US | claimed |
| CN-119677866-A | Substrate cleavage for nucleic acid synthesis | 特韦斯特生物科学公司 | 2025-03-21 | — | — | CN | claimed |
| EP-4504959-A1 | SUBSTRATE CLEAVAGE FOR NUCLEIC ACID SYNTHESIS | Twist Bioscience Corporation (US) | 2025-02-12 | — | — | EP | claimed |
| US-20240344057-A1 | METHODS OF SYNTHESIZING OLIGONUCLEOTIDES USING TETHERED NUCLEOTIDES | Twist Bioscience Corporation | 2024-10-17 | — | — | US | claimed |
| WO-2023196499-A1 | SUBSTRATE CLEAVAGE FOR NUCLEIC ACID SYNTHESIS | Twist Bioscience Corporation (US) | 2023-10-12 | — | — | WO | claimed |
| EP-4229210-A1 | METHODS OF SYNTHESIZING OLIGONUCLEOTIDES USING TETHERED NUCLEOTIDES | Twist Bioscience Corporation (US) | 2023-08-23 | — | — | EP | claimed |
| WO-2022086866-A1 | METHODS OF SYNTHESIZING OLIGONUCLEOTIDES USING TETHERED NUCLEOTIDES | Twist Bioscience Corporation (US) | 2022-04-28 | — | — | WO | claimed |
| US-20260132223-A1 | CLEAVABLE LINKERS FOR THE TETHERING OF POLYMERASES TO NUCLEOTIDES | ANSA BIOTECHNOLOGIES INC (US) | 2026-05-14 | — | — | US | disclosed |
| EP-4731762-A2 | DE NOVO STEPWISE TEMPLATE-INDEPENDENT SYNTHESIS OF LONG POLYNUCLEOTIDES | Ansa Biotechnologies, Inc. (US) | 2026-04-29 | — | — | EP | disclosed |
| US-20250369027-A1 | SUBSTRATE CLEAVAGE FOR NUCLEIC ACID SYNTHESIS | TWIST BIOSCIENCE CORP (US) | 2025-12-04 | — | — | US | disclosed |
| EP-4594480-A2 | CLEAVABLE LINKERS FOR THE TETHERING OF POLYMERASES TO NUCLEOTIDES | Ansa Biotechnologies, Inc. (US) | 2025-08-06 | — | — | EP | disclosed |
| WO-2024073349-A9 | CLEAVABLE LINKERS FOR THE TETHERING OF POLYMERASES TO NUCLEOTIDES | ANSA BIOTECHNOLOGIES, INC. (US) | 2025-04-03 | — | — | WO | disclosed |
| CN-119677866-A | Substrate cleavage for nucleic acid synthesis | 特韦斯特生物科学公司 | 2025-03-21 | — | — | CN | disclosed |
| WO-2018229173-A1 | COMPOSITIONS AND METHODS FOR IMPROVING THE THERMAL STABILITY OF NUCLEIC ACID AMPLIFICATION REAGENTS | ROCHE DIAGNOSTICS GMBH (DE) | 2018-12-20 | — | — | WO | disclosed |
| US-20170166603-A1 | LARGE STOKES SHIFT DYES | Life Technologies Corporation | 2017-06-15 | — | — | US | disclosed |
| US-9624424-B2 | Large stokes shift dyes | Life Technologies Corporation (US) | 2017-04-18 | — | — | US | disclosed |
| US-20150090936-A1 | LARGE STOKES SHIFT DYES | Life Technologies Corporation | 2015-04-02 | — | — | US | disclosed |
| US-20110313129-A1 | LARGE STOKES SHIFT DYES | Life Technologies Corporation (US) | 2011-12-22 | — | — | US | disclosed |
| EP-2396318-A2 | LARGE STOKES SHIFT DYES | Life Technologies Corporation (US) | 2011-12-21 | — | — | EP | disclosed |
| WO-2010093726-A2 | LARGE STOKES SHIFT DYES | Life Technologies Corporation (US) | 2010-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150090936-A1 | LARGE STOKES SHIFT DYES | SLC7A5, SLC43A1, HCCS | POLB 4822/4885P2RY1 4221/4885ENPP1 4640/4885 |
| US-20170166603-A1 | LARGE STOKES SHIFT DYES | SLC7A5, SLC43A1, HCCS | POLB 4822/4885P2RY1 4221/4885ENPP1 4640/4885 |
| US-20110313129-A1 | LARGE STOKES SHIFT DYES | SLC7A5, SLC43A1, HCCS | POLB 4822/4885P2RY1 4221/4885ENPP1 4640/4885 |
| US-20260132223-A1 | CLEAVABLE LINKERS FOR THE TETHERING OF POLYMERASES TO NUCLEOTIDES | POLN, PCNA, POLB | POLB 3/4885P2RY1 3041/4885ENPP1 280/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.